

Author: Gensicke Henrik Leppert David Yaldizli Özgür Lindberg Raija L.P. Mehling Matthias Kappos Ludwig Kuhle Jens
Publisher: Adis International
ISSN: 1172-7047
Source: CNS Drugs, Vol.26, Iss.1, 2012-01, pp. : 11-37
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry, Vol. 16, Iss. 36, 2009-12 ,pp. :





